Ricerca Announces Business Development Agreement with LSP
Ricerca Biosciences, a preclinical contract research drug development company, is pleased to announce a business development agreement with Life Science Partner (LSP) Co., Ltd., of Tokyo, Japan. Ricerca offers a spectrum of services for the areas of agrochemical registration, environmental analysis and pre-investigational new drug (IND) biopharmaceutical registration.
The collaboration and settlement grants LSP the ability to market the full spectrum of services offered by Ricerca to those companies represented by LSP, increasing the Japanese, Korean and overall Asian markets for Ricerca.
“We also believe our collaboration will largely help our customers develop new compounds and products for tomorrow and will provide higher value to meet customerneeds,” stated LSP Executive Director, Hiroko Suzuki.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
